AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39217570
Drug: GMRx2 ¼
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMRx2 ¼ dose (telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg)
Trial: 39217570
Drug: GMRx2 ½
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMRx2 ½ dose (telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg)
Trial: 39217605
Drug: GP IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa inhibitors (eptifibatide or tirofiban)
Trial: 39217605
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy without GP IIb/IIIa inhibitors
Trial: 39217615
Drug: Atrial fibrillation
RxNorm normalized name: Atrial Fibrillation Betapace 80 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial fibrillation screening enhanced by NT-proBNP; NT-proBNP concentrations measured, single-lead ECG registered once if NT-proBNP <125 ng/L, prolonged screening if NT-proBNP ≥125 ng/L.
Trial: 39217615
Drug: Low NT-proBNP
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NT-proBNP group (NT-proBNP <125 ng/L).
Trial: 39217809
Drug: Peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon beta-1a (125 µg subcutaneous every two weeks)
Trial: 39217809
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (30 µg intramuscular once a week)
Trial: 39218222
Drug: FPG ≤100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG ≤100 mg/dl
Trial: 39218222
Drug: FPG >100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG >100 mg/dl
Trial: 39218222
Drug: Metabolically active
RxNorm normalized name: Viable and metabolically active allogeneic human NIKS keratinocytes and human dermal fibroblasts cellularized layered scaffold
DrugBank: Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen (DB16709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolically active drugs
Trial: 39218235
Drug: Glucocorticoids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids treatment
Trial: 39218777
Drug: Immediate soft-tissue
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate soft-tissue augmentation (STA) during the same surgical procedure (Control group)
Trial: 39218777
Drug: Delayed soft-tissue
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed soft-tissue augmentation (STA) performed 3 months later (Test group)
Trial: 39218875
Drug: Gender-affirming hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gender-affirming hormonal therapy (GAHT) for 12 weeks
Trial: 39218935
Drug: Reduced-dose chemotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose chemotherapy (RDC) followed by blinatumomab for 2 weeks
Trial: 39218935
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (RDC + blinatumomab)
Trial: 39219192
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for HCV
Trial: 39219492
Drug: Omaveloxolone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omaveloxolone 150 mg orally once daily on an empty stomach
Trial: 39219857
Drug: Intradermal Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Bacillus Calmette-Guérin (BCG) injection
Trial: 39220573
Drug: CM310 300
RxNorm normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM310 300 mg subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and 300 mg CM310 Q2W for a total of 14 doses during the maintenance period.
Trial: 39220573
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously every 2 weeks (Q2W) for a total of 12 doses during the double-blind treatment period and placebo Q2W for a total of 14 doses during the maintenance period.
Trial: 39221160
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (waiting list, treatment after 27 days)
Trial: 39222035
Drug: Flecainide for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide for 3 months (150 mg once daily in a sustained-release dose)
Trial: 39222035
Drug: Flecainide for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide for 6 months (150 mg once daily in a sustained-release dose)
Trial: 39222035
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (no additional treatment for 6 months)
Trial: 39222348
Drug: Prescription Digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Digital Therapeutics (PDT)
Trial: 39222391
Drug: Rectal enema
RxNorm normalized name: Fleet Rectal Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal enema
Trial: 39222391
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (oral preparation and rectal enema)
Trial: 39222513
Drug: OC-Auto FIT
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-Auto FIT (threshold >100 ng/mL)
Trial: 39222896
Drug: TEER group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEER group (TriClip System + medical therapy)
Trial: 39222964
Drug: DOT Diary
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOT Diary (automated directly observed therapy app)
Trial: 39223302
Drug: Insufflation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insufflation of carbon dioxide (CO2) during laparoscopic surgery, specific dosage and duration not mentioned
Trial: 39223504
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous Zoledronic acid (ZOL)
Trial: 39223526
Drug: Nebulized N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized N-acetylcysteine (NAC) therapy over 12 weeks
Trial: 39223545
Drug: Raltitrexed (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (3 mg/m²) plus Irinotecan
Trial: 39223617
Drug: modified prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified prolonged exposure therapy (mPE) + treatment as usual (TAU)
Trial: 39223617
Drug: modified prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified prolonged exposure therapy (mPE)
Trial: 39223953
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy sessions
Trial: 39224580
Drug: Pharmacopuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacopuncture therapy (PPT)
Trial: 39224811
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with paclitaxel (50 mg/m2) and carboplatin (AUC=2) followed by concurrent CRT with the same regimen, radiation dose of 40 Gy over 16 fractions (2.5 Gray/fraction).
Trial: 39224901
Drug: CMAB015 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMAB015 (150 mg)
Trial: 39225259
Drug: Plozasiran 25
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 25 mg
Trial: 39225259
Drug: Plozasiran 50
RxNorm normalized name: Plozasiran
DrugBank: Plozasiran (DB18997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran 50 mg
Trial: 39225259
Drug: Plozasiran (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plozasiran (both doses)
Trial: 39225258
Drug: Edoxaban monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban monotherapy
Trial: 39225258
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Trial: 39225267
Drug: Asundexian 50
RxNorm normalized name: Asundexian
DrugBank: Asundexian (DB19088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asundexian 50 mg once daily
Trial: 39225267
Drug: Apixaban (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (standard dose)
Trial: 39225670
Drug: Acamprosate (666
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (666 mg dose 3 times daily)
Trial: 39226247
Drug: CS-ADL (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-ADL (Cognitive Stimulation in Activities of Daily Living)
Trial: 39226288
Drug: β-alanine supplementation
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-alanine supplementation (5g per dosage, total 155g over 7 days)
Trial: 39226292
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Tamoxifen (LDT) at 10 mg every other day
Trial: 39226292
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Tamoxifen (LDT) + Intermittent caloric restriction (ICR)
Trial: 39226514
Drug: Trimodality therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimodality therapy (radiation with radiosensitizing chemotherapy)
Trial: 39226704
Drug: Intraosseous (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous (IO) administration of 2-g TXA prehospital bolus; 11 participants
Trial: 39226704
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 2-g TXA prehospital bolus; 334 participants
Trial: 39226704
Drug: Intraosseous (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous (IO) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 13 participants
Trial: 39226704
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 299 participants
Trial: 39226719
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TRE and LCD (TRE + LCD)
Trial: 39227453
Drug: CC or
RxNorm normalized name: BD Syringe 10cc Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC or CT genotypes
Trial: 39227508
Drug: ESK981 160
RxNorm normalized name: ESK981
DrugBank: ESK981 (DB18155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESK981 160 mg once daily for 5 days per week for 4 weeks per cycle
Trial: 39227583
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (200 mg IV) every three weeks for two cycles
Trial: 39227626
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D adequate (> 30 ng/mL)
Trial: 39227818
Drug: FOS-fructans (2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOS-fructans (2.1 g/day)
Trial: 39227818
Drug: Gluten (5.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten (5.7 g/day)
Trial: 39227921
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LCD and TRE
Trial: 39228131
Drug: Artesunate-amodiaquine (200/540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine (200/540 mg daily for 3 days)
Trial: 39228131
Drug: Dihydroartemisinin-piperaquine (40/960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (40/960 mg daily for 3 days)
Trial: 39229259
Drug: All vaccine
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccine combinations
Trial: 39229468
Drug: Dalpiciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (150 mg) plus letrozole/anastrozole
Trial: 39229468
Drug: Dalpiciclib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (150 mg) plus fulvestrant
Trial: 39229468
Drug: Dalpiciclib (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (175 mg) plus letrozole/anastrozole
Trial: 39229468
Drug: Dalpiciclib (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (175 mg) plus fulvestrant
Trial: 39229468
Drug: Dalpiciclib (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (lower doses) plus letrozole/anastrozole
Trial: 39229468
Drug: Dalpiciclib (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalpiciclib (lower doses) plus fulvestrant
Trial: 39230545
Drug: CSL112 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (6 g, 4 weekly infusions)
Trial: 39230829
Drug: 350/700 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350/700 mg BAM + ETE
Trial: 39230885
Drug: Aficamten (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (5-20 mg daily)
Trial: 39231342
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of Lu AG09222
Trial: 39231855
Drug: Nofazinlimab 200
RxNorm normalized name: Nofazinlimab
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nofazinlimab 200 mg every 3 weeks (Q3W)
Trial: 39231898
Drug: Angiotensin-(1-7) infusion
RxNorm normalized name: Angiotensin (1-7)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-(1-7) infusion at 10 mcg/Kg day for a maximum of 7 days (Phase 2)
Trial: 39232408
Drug: nab-paclitaxel (nab-P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel (nab-P) 100 mg/m² on days 1 and 8, carboplatin (C) on day 1, every 3 weeks for 6 cycles
Trial: 39232496
Drug: CMG901 (Claudin18.2-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMG901 (Claudin18.2-specific antibody-drug conjugate)
Trial: 39232602
Drug: Spirulina (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (1 g twice daily for 14 days)
Trial: 39232634
Drug: Alirocumab 75
RxNorm normalized name: alirocumab 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab 75 to 150 mg every 2 weeks subcutaneously
Trial: 39232760
Drug: Shoulder massage
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoulder massage administered twice at 6-hour intervals
Trial: 39232761
Drug: Fuzuloparib 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 60 mg BID plus mFOLFIRINOX q2w for 8-12 cycles followed by maintenance fuzuloparib at 150 mg BID
Trial: 39232761
Drug: Fuzuloparib 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 30 mg BID
Trial: 39232761
Drug: Fuzuloparib 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 60 mg BID
Trial: 39232761
Drug: Fuzuloparib 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib 100 mg BID
Trial: 39232792
Drug: Multicomponent physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent physical training programme (progressive and supervised endurance, resistance and balance training for 4 weeks, twice weekly sessions, total of 8 sessions)
Trial: 39232999
Drug: Adjunctive pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive pneumatic compression
Trial: 39233312
Drug: Belzutifan 200
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan 200 mg once daily
Trial: 39234416
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg each) administered subcutaneously every 4 weeks (n=9)
Trial: 39235513
Drug: sodium hypochlorite/amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium hypochlorite/amino acid gel and crosslinked hyaluronic acid (xHyA) with subgingival instrumentation
Trial: 39235596
Drug: Sitravatinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib monotherapy
Trial: 39235596
Drug: Sitravatinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitravatinib monotherapy and sitravatinib plus tislelizumab
Trial: 39235772
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg daily for 8 weeks
Trial: 39235853
Drug: SteWARdS Antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SteWARdS Antibiotic Defence app (intervention group)
Trial: 39236733
Drug: Casirivimab and
RxNorm normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Casirivimab and imdevimab (150-1200 mg intravenously or 600-1200 mg subcutaneously) administered before or at the same time as mRNA-1273 vaccination
Trial: 39236733
Drug: Casirivimab and
RxNorm normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Casirivimab and imdevimab administered 48 mg and 12 mg intravenously
Trial: 39236733
Drug: mRNA-1273 administered
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 administered 6 days before mAb
Trial: 39236736
Drug: IIS (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIS (10 mg/kg infliximab)
Trial: 39236736
Drug: AIS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIS (5 mg/kg infliximab, accelerated induction)
Trial: 39236736
Drug: SIS (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIS (5 mg/kg infliximab, standard induction)
Trial: 39236984
Drug: Isotoxically dose-escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotoxically dose-escalated chemoradiotherapy (60-74 Gy in 30-37 fractions)
Trial: 39237135
Drug: Product A
RxNorm normalized name: Vaccine product against severe acute respiratory syndrome coronavirus 2 (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product A (iso-osmolar dose)
Trial: 39237135
Drug: Product B
RxNorm normalized name: Product base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product B (iso-osmolar escalation dose)
Trial: 39237135
Drug: Product C
RxNorm normalized name: Product containing plant agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product C (hypo-osmolar escalation dose)
Trial: 39237158
Drug: Standard CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CT scan with intravenous contrast
Trial: 39237273
Drug: Digital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital therapy programme using a smartphone application based on individual health data, duration of 180 days (90-day in-life phase followed by a 90-day follow-up phase).
Trial: 39237273
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for the treatment of primary arterial hypertension, duration of 180 days.
Trial: 39237283
Drug: Standardised intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised intervention for announcing decisions of withholding or withdrawing life-sustaining treatments
Trial: 39237427
Drug: Pomalidomide 4
RxNorm normalized name: pomalidomide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomalidomide 4 mg orally daily from days 1 to 21; Daratumumab 16 mg/kg intravenously on specified days; Dexamethasone 40 mg (age ≤ 75 years) or 20 mg (age > 75 years) orally on specified days.
Trial: 39238363
Drug: Monthly linear
RxNorm normalized name: Aspalathus linearis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly linear decrease in QMNC index over time
Trial: 39239277
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with docetaxel and cisplatin (TP) followed by radiation.
Trial: 39239277
Drug: TP plus
RxNorm normalized name: Unifine Pentp Plus 4mm x 33g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP plus PD-1 inhibition by pembrolizumab (MK-3475; 200 mg i.v. starting day 1 q3w for 17 cycles).
Trial: 39240567
Drug: Colchicine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.5 mg twice daily for 3 days, then 0.5 mg daily thereafter)
Trial: 39241203
Drug: Nivolumab 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles
Trial: 39241203
Drug: Nivolumab 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m² for four cycles (including reTURBT)
Trial: 39241211
Drug: Imlunestrant monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imlunestrant monotherapy (n = 114)